AI Summary
This clinical practice guideline focuses on the diagnosis, treatment, and follow-up of human immunodeficiency virus-associated lymphomas, specifically non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL). Despite a decrease in the incidence of HIV-associated NHL with the introduction of combination antiretroviral therapy (ART), NHL remains a common type of cancer in individuals living with HIV. Incidences of HIV-associated NHL and HIV-associated HL are increased approximately 10- to 20-fold compared to the general population.
Non-Hodgkin lymphoma (NHL) remains the most common type of cancer and a leading cause of mortality in people who are living with human immunodeficiency virus (HIV).1 This is despite a marked decrease in the incidence of HIV-associated NHL (HIV–NHL) following the introduction of combination antiretroviral therapy (ART) in the mid-1990s.2 In contrast, the incidence of Hodgkin lymphoma (HL) increased slightly but has remained stable since 2000.1 Compared with the age- and gender-matched general population, the incidences of HIV–NHL and HIV-associated HL (HIV–HL) are increased ∼10- to 20-fold.